Earnings call transcript: SANUWAVE’s Q4 2025 revenue hits record, stock dips premarket

SANUWAVE reported record Q4 2025 revenue of $13.4M, up 30% YoY, with net income of $7.7M (vs. a $13.3M loss prior year) and adjusted EBITDA of $4.8M. Management guides Q1 2026 revenue of $9.6M–$10.3M (up 3%–10% YoY) and full-year 2026 growth of 16%–25%, while noting industry disruption from CMS reimbursement changes. Despite strong results and UltraMIST unit momentum (255 systems in Q4; 624 for the year), the stock fell ~5% premarket to $17.90 and faces near-term customer/audit risks and sales-tax remediation costs.

Analysis

The most important dynamic is a channel shift rather than a pure demand story: moving sales to stocking resellers creates short-term revenue and timing volatility but structurally reduces per-unit go-to-market cost and raises incremental operating leverage over 6–12 months as reorders normalize. That amplifies second-order winners — consumables-heavy business models and contract manufacturers with capacity to absorb higher recurring volumes — while it disproportionately hurts firms whose revenue is concentrated in high‑margin, audit‑sensitive one‑offs (skin substitutes/allografts), which face both reimbursement pressure and downstream customer insolvency risk.

Operational execution is the gating factor. Mold qualification and ERP/reseller integration are the two operational milestones that will determine whether gross margins and active-install metrics improve or whether channel inventory and sales tax remediation continue to create noise. Near-term headlines (earnings prints, state sales tax findings, audit announcements) will move sentiment; durable improvement requires 3–12 months of consistent reseller replenishment data and visible consumables cadence.

From a valuation-convergence perspective the market appears to be pricing a long-tail contagion that may be overstated: UltraMIST-like consumable models typically re-expand once payers and practitioners settle into new coding/coverage norms. The obvious asymmetry is that downside from a lost customer base is tangible and rapid (high audit/clawback tail), while upside — new reseller penetration and faster consumable attach — compounds over multiple quarters. Monitor active-system reorders, reseller inventory weeks, and the new manufacturing line ramp as primary catalysts that will re-rate risk premia.

Key Decisions for Investors

• Long SNWV via a 12–18 month call spread (buy longer-dated call ~25% OTM, finance with a further OTM short) sized 2–3% of portfolio. Rationale: captures margin/take‑rate improvement from reseller roll-out and consumables re‑acceleration; max loss = premium paid, upside asymmetry ~3x–5x if resellers ramp within 6–12 months. Close or trim into the first clear quarter of sustained reseller reorders.
• Sell cash‑secured puts on SNWV with a 3–6 month tenor at a strike ~20–30% below current levels to collect yield and potentially acquire stock at a lower basis. Rationale: if you have constructive medium-term view but want downside protection; risk = assignment at strike (manage position size so max notional ≤ target allocation).
• Pair trade: long SNWV equity (or its LEAP exposure) vs short the health‑care small‑cap ETF XHE, horizon 6–12 months. Rationale: isolates idiosyncratic upside from SNWV’s consumables/ reseller execution while hedging sector/audit contagion risk; aim for a modest net long exposure (1–2% portfolio) and rebalance after quarterly prints.